Showing 41,201 - 41,220 results of 44,189 for search '"In Treatment"', query time: 0.24s Refine Results
  1. 41201

    Pien Tze Huang Attenuates Neuro-inflammatory Injury in BV2 Microglial Cells Induced by Lipopolysaccharide via Inhibition of TLR4/MAPK Signaling Pathway by Zhenwei HUANG, Qing ZHANG, Lili HUANG, Xiaoqin ZHANG, Mingqing HUANG

    Published 2021-02-01
    “…And then its absorbance at 490 nm was detected after the treatment of MTT for 4 h. BV2 microglial cells were seeded at a density of 5×10<sup>4</sup>cells/mL in 24-well plate. …”
    Get full text
    Article
  2. 41202

    Screening of Genes Related to Resistance to Bacterial Leaf Blight in Oryza officinalis by using RNA-seq Technology by Yayun YANG, Feifei ZHANG, Famei ZHANG, Xinxiang A, Chao DONG, Cuifeng TANG, Chunyun YANG, Luyuan DAI

    Published 2024-11-01
    “…GO functional enrichment analysis revealed that PXO99 treatment resulted in a total of 45 significantly enriched GO categories in biological processes. …”
    Get full text
    Article
  3. 41203
  4. 41204

    Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3+ CD8+ T Cells and Survival in Diffuse Large B Cell Lymphoma by Tingting Zhang, Tianyuan Ren, Zheng Song, Jing Zhao, Lei Jiao, Zhenzhen Zhang, Jin He, Xianming Liu, Lihua Qiu, Lanfang Li, Shiyong Zhou, Bin Meng, Qiongli Zhai, Xiubao Ren, Zhengzi Qian, Xianhuo Wang, Huilai Zhang

    Published 2020-01-01
    “…Patients with Tim-3+ TILs and exhausted Tim-3+ CD8+ T cells exhibited inferior survival, thus highlighting the possibility of potential therapeutic applications of the inhibition of Tim-3 alone or in combination with other immune checkpoints for treatment of patients with DLBCL.…”
    Get full text
    Article
  5. 41205

    Comparison of immune responses to SARS-CoV-2 spike following Omicron infection or Omicron BA.4/5 vaccination in kidney transplant recipients by Inga Tometten, Tobias Brandt, Maike Schlotz, Ricarda Stumpf, Sinje Landmann, Marta Kantauskaite, Joshua Lamberti, Jonas Hillebrandt, Lisa Müller, Margarethe Kittel, Katrin Ivens, Katrin Ivens, Henning Gruell, Anja Voges, Heiner Schaal, Nadine Lübke, Eva Königshausen, Eva Königshausen, Lars Christian Rump, Lars Christian Rump, Florian Klein, Florian Klein, Florian Klein, Johannes Stegbauer, Johannes Stegbauer, Jörg Timm

    Published 2025-01-01
    “…Tixagevimab/Cilgavimab treatment was associated with robust neutralization of the Wuhan strain, but ineffective against XBB.1.5.ConclusionThe BA.4/5 vaccine improved neutralizing activity against the BA.4/5 variant, but not against the subsequently circulating XBB.1.5 variant in KTRs. …”
    Get full text
    Article
  6. 41206
  7. 41207

    Protective mechanism of safflower yellow injection on myocardial ischemia-reperfusion injury in rats by activating NLRP3 inflammasome by Lingmei Li, Ce Cao, Hao Guo, Li Lin, Lei Li, Yehao Zhang, Gaojie Xin, Zixin Liu, Shujuan Xu, Xiao Han, Qiong Zhang, Jianhua Fu

    Published 2025-01-01
    “…In addition, the activities of myocardial enzymes, the contents of inflammatory factors, the expressions of inflammatory-related proteins, autophagy-related proteins, autophagosome-related proteins, Bax and Caspase-3 were increased, while Bcl-2 and Bcl-2/Bax were decreased. SYI treatment reversed these trends, except for the expression of autophagosome-related proteins. …”
    Get full text
    Article
  8. 41208

    Risk of aortic aneurysm or dissection following use of fluoroquinolones: a retrospective multinational network cohort studyResearch in context by Jack L. Janetzki, Jung Ho Kim, Evan Minty, Jung Ah Lee, Daniel R. Morales, Rohan Khera, Chungsoo Kim, Thamir M. Alshammari, Scott L. DuVall, Michael E. Matheny, Thomas Falconer, Seonji Kim, Thanh-Phuc Phan, Phung-Anh Nguyen, Min-Huei Hsu, Jason C. Hsu, Rae Woong Park, Kenneth K.C. Man, Sarah Seager, Mui Van Zandt, James P. Gilbert, Patrick B. Ryan, Martijn J. Schuemie, Marc A. Suchard, George Hripcsak, Nicole Pratt, Seng Chan You

    Published 2025-03-01
    “…The study included 13,588,837 patients aged 35 or older who initiated systemic fluoroquinolones (FQs) or comparable antibiotics (trimethoprim with or without sulfamethoxazole [TMP] or cephalosporins [CPHs]) for UTI treatment in the outpatient setting between JAN 01, 2010 and DEC 31, 2019. …”
    Get full text
    Article
  9. 41209
  10. 41210
  11. 41211

    The concerted actions of microRNA-29a and interferon-β modulate complete Freund's adjuvant-induced inflammatory pain by regulating the expression of type 1 interferon receptor, int... by Chien-Cheng Liu, Kuo-Chuan Hung, Yu-Yu Li, Eagle Yi-Kung Huang, Chin-Chen Chu, Lok-Hi Chow, Ping-Heng Tan

    Published 2025-03-01
    “…Results: Our results demonstrated elevated miR-29a expression (CFA 3 days: mean difference [95% confidence interval, CI]: 0.860 [0.657–1.062]; CFA 5 days: mean difference [95% CI]: 1.120 [0.917–1.322], P<0.001, n=6) and decreased IFNR1 expression (CFA 3 days: mean difference [95% CI]: −0.300 [−0.470 to −0.130]; CFA 5 days: mean difference [95% CI]: −0.330 [−0.515 to −0.145], P=0.004, n=6) from Days 3–5 post-CFA induction, with IFN-ß expression showing a significant increase from Day 2 (F [3.30, 16.5]=34.3 for factor time, P≤0.01, n=6). Treatment with an miR-29a inhibitor alleviated CFA-induced mechanical allodynia and thermal hyperalgesia by Day 5 (P<0.001, n=9), concomitant with upregulation of IFNR1 and ISG15 expression, and downregulation of p-ERK (IFNR1; CFA 5 days + miR-29a inhibitor vs CFA 5 days; mean difference [95% CI]: 30.00 [20.31–39.69]; ISG15 conjugates; CFA 5 days + miR-29a inhibitor vs CFA 5 days, mean difference [95% CI]: 1.000 [0.9144–1.086]; free ISG15, mean difference [95% CI]: 2.402 [2.171–2.633]; p-ERK; CFA 5 days + miR-29a inhibitor vs CFA 5 days, mean difference [95% CI]: −32.00 [−34.10 to −29.90], P<0.001, n=9). …”
    Get full text
    Article
  12. 41212

    Analysis of nanomedicine applications for inflammatory bowel disease: structural and temporal dynamics, research hotspots, and emerging trends by Hong-Yu Jiang, Hong-Yu Jiang, Bo Shao, Bo Shao, Hong-Da Wang, Hong-Da Wang, Wen-Qi Zhao, Shao-Hua Ren, Shao-Hua Ren, Shao-Hua Ren, Yi-Ni Xu, Yi-Ni Xu, Tong Liu, Tong Liu, Cheng-Lu Sun, Cheng-Lu Sun, Yi-Yi Xiao, Yi-Yi Xiao, Yi-Cheng Li, Yi-Cheng Li, Qiang Chen, Qiang Chen, Peng-Yu Zhao, Peng-Yu Zhao, Guang-Mei Yang, Guang-Mei Yang, Xu Liu, Xu Liu, Yu-Fan Ren, Yu-Fan Ren, Hao Wang, Hao Wang, Hao Wang

    Published 2025-01-01
    “…This interdisciplinary field, which spans materials science, pharmacy, and medicine, has seen influential publications mainly concentrated on targeted nanoparticles treatment for IBD. Keyword analysis revealed that current research hotspots include drug delivery, immune cell regulation, antioxidant damage, intestinal microbiota homeostasis, and nanovesicles.ConclusionThis study offers a comprehensive overview of global research landscape, emphasizing the rapid growth and increasing complexity of this field. …”
    Get full text
    Article
  13. 41213

    Comparison of outcome and toxicity of postoperative intensity‐modulated radiation therapy with two‐dimensional radiotherapy in patients with soft tissue sarcoma of extremities and... by Jianyang Wang, Yongwen Song, Xinfan Liu, Jing Jin, Weihu Wang, Zihao Yu, Yueping Liu, Ning Li, Hui Fang, Hua Ren, Yuan Tang, Yu Tang, Bo Chen, Ningning Lu, Shunan Qi, Shulian Wang, Yexiong Li

    Published 2019-03-01
    “…Conclusions When compared with conventional techniques, postoperative IMRT seems to provide better LRFS, DMFS, DFS, and OS and less late toxicities in patients with STS of extremities and trunk, which should be offered as a preferred treatment.…”
    Get full text
    Article
  14. 41214

    Targeting protein kinase C-α prolongs survival and restores liver function in sepsis: Evidence from preclinical models by Ling Xiong, Dustin Beyer, Na Liu, Tina Lehmann, Sophie Neugebauer, Sascha Schaeuble, Oliver Sommerfeld, Philipp Ernst, Carl-Magnus Svensson, Sandor Nietzsche, Sebastian Scholl, Tony Bruns, Nikolaus Gaßler, Markus H. Gräler, Marc Thilo Figge, Gianni Panagiotou, Michael Bauer, Adrian T. Press

    Published 2025-02-01
    “…Midostaurin is the clinically approved active pharmaceutical ingredient in Rydapt, approved for the adjuvant treatment of FTL3-mutated AML. Here, it reduced plasma bile acids and related inflammation in those patients, opening a translational avenue for therapeutics in sepsis. …”
    Get full text
    Article
  15. 41215
  16. 41216
  17. 41217
  18. 41218
  19. 41219
  20. 41220

    Liver cancer risk and changes in lifestyle habits after successful hepatitis C virus therapy post-DAA HCV therapy: lifestyle changes and liver cancer risk by Núria Granel, Gemma Iserte, Concepció Bartres, Neus Llarch, Anna Pla, Víctor Sapena, Zoe Mariño, Sabela Lens, Ramón Vilana, Isabel Nuñez, Anna Darnell, Ernest Belmonte, Ángeles García-Criado, Alba Díaz, Marco Sanduzzi-Zamparelli, Carla Fuster, Sergio Muñoz-Martínez, Carmen Ayuso, Jordi Rimola, Alejandro Forner, Alexandre Soler, Ferran Torres, José Ríos, Jordi Bruix, Andrew M. Moon, Xavier Forns, María Reig

    Published 2025-02-01
    “…Our study investigates lifestyle changes that occur in HCV patients with Sustained Virological Response (SVR) after direct-acting antiviral (DAA) treatment. Methods In this prospective, single-center study, HCV patients with advanced liver disease (F3/F4) treated and cured with DAA were invited to fill a lifestyle habits questionnaire in and perform abdominal ultrasound (US), blood extraction and anthropometric measurements within the 1st month after SVR and every 6 months thereafter until 48 months of follow-up, LC development, death, or loss to follow-up. …”
    Get full text
    Article